| Literature DB >> 32373362 |
Narendra Pandit1, Tek Narayan Yadav1, Laligen Awale1, Kunal Bikram Deo1, Yogesh Dhakal2, Shailesh Adhikary1.
Abstract
OBJECTIVE: With the adoption of safe cholecystectomy principles at an academic institute, the risk of major bile duct injury has decreased. This study aims at evaluating the present status of bile duct injury, compared to the study published in 2013 by index centre.Entities:
Year: 2020 PMID: 32373362 PMCID: PMC7191355 DOI: 10.1155/2020/4382307
Source DB: PubMed Journal: Minim Invasive Surg ISSN: 2090-1445
Figure 1Magnetic resonance cholangiopancreatography (MRCP) showing Strasberg's type E2 injury following open cholecystectomy.
Demographics, details of index operation, presentation, and staging of injury.
| Parameters | Total patients, |
| Age (years), mean (range) | 40 (16–55) |
| Male : female (M : F) | 7 : 11 |
|
| |
|
| |
| Outside hospital | 5 (27.8%) |
| In hospital | 13 (72.2%) |
|
| |
|
| |
| Biliary colic | 9 (50%) |
| Acute cholecystitis | 4 (22.2%) |
| Mucocele | 4 (22.2%) |
| Xanthogranulomatous cholecystitis | 1 (5.5%) |
|
| |
|
| |
| Open | 3 (16.7%) |
| Laparoscopic | 15 (83.3%) |
| Any conversion from laparoscopy to open | 0 |
|
| |
|
| |
| Dissection of hepatocystic triangle first | 13 (72.2%) |
| Unknown | 5 (27.8%) |
|
| |
|
| |
| Critical view of safety | 11(61.1%) |
| Infundibular approach | 1(5.5%) |
| Top-down | 1(5.5%) |
| Unknown | 5(27.8%) |
|
| |
|
| |
| Intraoperative | 4 (22.2%) |
| Postoperative | 14 (77.8%) |
|
| |
|
| |
| Open | 3 (16.7%) |
| Laparoscopic | 15 (83.3%) |
|
| |
|
| |
| End-to-end anastomosis + T-tube | 1(5.5%) |
| Hepaticojejunostomy | 2 (11.1%) |
| Suture closure of rent in common hepatic duct | 1 (5.5%) |
|
| |
|
| |
| Jaundice | 5 (29.4%) |
| Intra-abdominal sepsis | 8(35.3%) |
| Biliary fistula | 2 (11.8%) |
|
| |
|
| |
| Intraoperative | 3 (16.7%) |
| 0–3 days | 3(16.7%) |
| 4–7 days | 3(16.7%) |
| 8 days–6 weeks | 5 (27.8%) |
| 6 weeks–3 months | 4 (22.2%) |
|
| |
|
| |
| A | 9 (50%) |
| D | 1 (5.5%) |
| E1 | 5(27.8%) |
| E2 | 1 (5.5%) |
| E3 | 2 (11.1%) |
| Vasculobiliary injury | 0 |
| Other organs injured | 0 |
Preoperative risk assessment, laboratory values, intraoperative events, and outcomes of operative group.
| Parameters | Results ( |
| Type II diabetes mellitus | 2 (20%) |
| Current smoker within 1 year | 5 (50%) |
| Hypertension requiring medication | 3 (30%) |
| Preoperative blood transfusions (red blood cells within 72 hr before surgery) | 1 (10%) |
| Sepsis within 48 hr before surgery | 0 |
| Cirrhosis | 0 |
| Mean hemoglobin (g/dl) | 11.6 ± 1.8 |
| Median total serum bilirubin, mg/dl (range) | 2.0 (0.8–18.0) |
| Albumin (g/dl) | 3.9 ± 0.25 |
|
| |
|
| |
| <24 hr | 3 (30%) |
| >7 days–<6 weeks | 3 (30%) |
| 8 to 12 weeks | 4 (40%) |
|
| |
|
| |
| Hepaticojejunostomy | 7 (70%) |
| End-to-end anastomosis + T-tube | 1 (10%) |
| Laparotomy + lavage + drainage | 2 (20%) |
| End-to-side hepaticojejunostomy | 2 (20%) |
| Side-to-side hepaticojejunostomy | 5 (50%) |
| Any form of liver resection | 0 |
| Superficial SSI | 2 (20%) |
| Mortality | 0 |
Figure 2Follow-up magnetic resonance cholangiopancreatography (MRCP) showing normal extrahepatic bile duct with bilioenteric continuity, following sealed cystic duct stump leak (Strasberg's type A injury).
Results of bile duct reconstruction.
| Parameters | |
|---|---|
| Length of follow-up, median (months) | 13 (8–36) |
| Lost to follow-up | 0 |
| Any evidence of restricture or recurrent cholangitis | 0 |
| Any postoperative interventions for anastomotic problems | 0 |
Comparison of the present study with the previous study from our centre.
| Parameters | Current study (2014–2019) | Previous study (2001–2010) |
|---|---|---|
| Total cholecystectomies (in-hospital) | 2,300 | 11,345 |
| Mean age, years, (range) | 40 (16–55) | 46.5 (23–68) |
| Referred | 5 (27.8%) | 15 (16.3%) |
| Index hospital | 13 (72.2%) | 77 (83.7%) |
|
| ||
|
| ||
| Major bile duct injury | 8 (0.35%) | |
| In-hospital major bile duct injury | 5 (0.21%) | 77 (0.68%) ( |
| Bile leak | 10 (0.43%) | NA |
| Morbidity | 2 (11.1%) | NA |
| Mortality (30 and 90 days) | 0 | 3 (3.3%) |
| Follow-up | ( | ( |
| Median follow-up (mo) | 13 | 31 |
| Restricture | 0 | 3 (4%) |
| Good outcome | 18 (100%) | 62 (82%) |